antigen challenge. In the final analysis, the role of mediators in everyday asthma is the crucial information required, but studying their role in bronchial hyperreactivity and antigen challenge is easier and may shed light on the relationship of induced bronchoconstriction to asthma.
It has been claimed that certain drugs are useful for asthma because they reduce bronchial reactivity or that drugs should be given in doses which will maintain a reduction in bronchial reactivity. 1 Some drugs such as the calcium antagonists reduce bronchial reactivity without causing bronchodilatation 2 while others such as atropine appear to cause bronchodilatation with little or no change in reactivity. 3 -4 Betaagonists appear to do both and there would seem at present to be no a priori way of knowing whether the benefit perceived by the patient is mainly due to the bronchodilatation or to the reduction in bronchial reactivity. It has also been claimed that changes in airway caliber may cause an apparent change in bronchial reactivity when measured by conventional tests, due to the change in airway size and not to any intrinsic change in airway responsiveness. 5 Drugs such as the calcium antagonists which reduce bronchial hyperreactivity without causing bronchodilatation have not been found to be of benefit in patients with asthma and are not recommended as treatment. Drugs such as atropine and ipratropium which cause litde or no change in bronchial reactivity are used in clinical practice. These studies raise several important questions.
• What is the relationship between change in airway caliber and change in bronchial reactivity with the different drugs used to treat asthma? Is there a difference between betaagonists and antimuscarinic drugs, for example?
• If there is a difference, does the patient benefit from the change in reactivity and, if so, why are calcium antagonists not helpful in asthma?
• If bronchoconstriction in asthma is due to repetitive bombardment of hyperreactive airways by different stimuli, why don't dregs which reduce hyperreactivity cause bronchodilatation in the long run, since they are presumably reducing the bronchoconstrietor responsiveness to these stimuli? 
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t is difficult to address the needs for future research into the causes of asthma without stepping back a bit to examine how our perceptions of this syndrome have changed over recent decades. Perhaps a convenient place to begin is in the latter part of the 1950s when I was a medical student who was just beginning to learn about clinical medicine. A standard and well-respected textbook of medicine contained two pages (out of a total of 1,775) on asthma with a portion of those two pages devoted to allergic rhinitis. 1 These two pages were found within a chapter dealing with allergic diseases. There was a brief description of histopathology. There was no pathophysiologic description and no mention of mediators, neural mechanisms or increased airway responsiveness. Functional assessment of the patient was not even mentioned. The therapeutic portion began with desensitization, and pharmacotherapeutics were limited to subcutaneous epinephrine, intravenous aminophylline, glucocorticosteroids, sedatives (which were recommended) and a suggestion that, with regard to opiates, meperidine should be used instead of morphine.
The most recent edition of that same text contained eight pages (out of a total of 2,212) comprising a chapter devoted solely to asthma. 2 Not only was there a greater than 400 percent increase in the space allotted to asthma (as contrasted with an overall page increase of 28 percent for the whole text), the chapter was richly filled with prevalence and incidence data, pathophysiology, pathobiology and histopathology and contained a sophisticated discussion of mediators (much of which will need to be modified and extended in the next edition) along with major and logical insights into the pharmacotherapeutics of this syndrome. Other respected textbooks of internal medicine have shown similar trends. Thus, even from a general and standard text of medicine, it was obvious that over the period of a quarter century, major advances had been made in the understanding and management of asthma.
The advances came from many sources. Of extreme importance was the recognition that active communication among persons from diverse disciplines was a requisite for CHEST lOi 16! JUNE, 1987 / Supplement the current degree of synthesis and application. Future directions of research will, if they are to be productive and ultimately applicable, continue to require active dialogue and collaboration among cell biologists, geneticists, biochemists, pathologists, pharmacologists, immunologists, epidemiologists, pulmonary physicians and allergists. It is clear that progress will continue to come in the form of multiple fragments that relate simple or complex stimuli to single or multiple responses using systems ranging from in vitro cultures of a single cell type (human or subhuman) all the way to persons actually suffering from asthma. Controversies both at the observational and interpretational levels will continue to arise, even when the simplest systems are being used.
The title of this workshop implies that we are discussing a single disease with an etiology that can be defined. I doubt that this is the true state of affairs. If we view asthma as a syndrome whose essential characteristic is increased responsiveness of airways, whether a preexisting characteristic or an inducible state, we have a point for beginning the next quarter century. We now suspect that this degree of airway responsiveness is a normally distributed attribute among the human population, that the degree of responsiveness can change within the population in response to infections and to pollution in the macro-and microenvironments, and that multiple factors come into play to determine this attribute and its change. We know very little about those who have increased responsiveness but do not have the clinical syndrome of asthma. We suspect that a complex interplay of neural, cellular and hormonal mechanisms plus chemical mediators and smooth muscle characteristics will be involved in producing the syndrome of asthma.
Significant progress has been made in recognizing and defining the similarities among asthmatics in terms of the nonspecificity of increased airway responsiveness. I suspect that we will continue to learn from studying and understanding such similarities. However, it is my guess that we will soon begin a new era and will further learn from the dissimilarities among asthmatic subjects. These dissimilarities may well be related to different degrees and cell type, mediator production, cell-to-cell interactions), can they be seen in other organ systems? I offer this partial listing with full awareness that some investigators think that they have at least partial answers to some of the questions posed. I am also aware that some partial answers are available from different animal species, yet I am also aware of enormous interspecies variations that prevent these partial answers from being straightforwardly applicable to human beings.
Finally, I wish to emphasize that each of the disciplines to which I have referred will need to play a prominent role if we are to make the coming 25 years as profitable and exciting as the previous ones have been.
